Samantha Truex
Investor
Cambridge, Massachusetts
Overview
Work Experience
Board Member, Chair of Nom & Gov Committee
2024 - Current
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Raised $231,504,600.00 from Deep Track Capital, Biotechnology Value Fund, Petrichor Healthcare Capital Management, Commodore Capital, RA Capital Management, OrbiMed and TCG Crossover.
Board Member, Chair of Compensation Committee
2022
Chief Executive Officer
2021 - 2024
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Raised $408,000,000.00 from Wellington Management, Access Biotechnology, Bain Capital Life Sciences, HBM Partners, Decheng Capital, HBM Healthcare Investments, Samsara BioCapital, Enavate Sciences, Venrock Healthcare Capital Partners and Altshuler Shaham.
Member of the Board; Chair of Audit Committee
2018 - 2022
Inspired by nature, HotSpot Therapeutics is moving beyond active site inhibition to allosterically target drivers of protein function and deliver first-in-class medicines with exceptional properties.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Raised $210,000,000.00 from Pavilion Capital, Revelation Partners, SR One, LSP BioVentures, Monashee Investment Management, B Capital, Atlas Venture, Sofinnova Partners, CaaS Capital Management and Pivotal bioVenture Partners.
CEO
2018 - 2021
Quench Bio sought to discover inhibitors of gasdermin, a novel target that plays a key role in inflammatory cell death. We aimed to provide effective therapies for patients with severe inflammatory diseases. Quench Bio raised a $50M Series A funded by Atlas Venture, RA Capital, Arix Bioscience and AbbVie Ventures. After almost 3 years of attempts to drug this interesting target, we wound down Quench and returned capital to the investors.
COO and Head of Corporate Development
2016 - 2017
Led Corporate Development activities, including corporate/financing strategy, partnering, legal and operational alliances across manufacturing, research and development. Drove evaluation of financing options and executed on competitive reverse merger process culminating in signing of merger with Mirna in May 2017.
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Raised $472,417,500.00 from Ginkgo Bioworks.
Chief Business Officer
2014 - 2016
Padlock Therapeutics was acquired by Bristol-Myers Squibb (BMS) in 2016. Padlock Therapeutics was a venture-funded biotech company focused on developing therapeutic inhibitors of a family of enzymes called protein-arginine deiminases (PADs).
VP Corporate Development
2013 - 2014
VP, Program Executive for Fampyra
2012 - 2013
Vice President, Business Development
2010 - 2012
Sr. Director, Head of Product and Commercial Development for Hemophilia
2008 - 2010
Sr. Director, Corporate Development
2006 - 2008
Head of Mergers and Acquisitions for Biogen Idec. Led M&A strategy/evaluations and interactions with investment bankers. Led acquisition of Syntonix in January 2007 and was instrumental in Biogen Idec sale process in Q4 2007.
Biogen is a biotechnology company engaged in the development of innovative therapies for neurological and neurodegenerative diseases.
Director, Business Development
1998 - 2006
Associate, Business Development
1997 - 1998